Genix Pharmaceuticals Corporation

GENPF

GENPFGenix Pharmaceuticals Corporation US flag

Other OTC

0.04

USD

- -

-0.05EPS

-0.80P/E

2.37MMarket Cap

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

CA37232A1093

Return %

Stock

S&P500

61.94

18.57

-70.37

40.07

-72.79

86.07

Use logarithmic scale

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	- -	0.02	0.02	0.01	0.02	0.02	0.01	0.01	- -	- -	- -	- -	- -	- -
Basic EPS, GAAP	- -	- -	-0.01	- -	-0.02	- -	-0.01	- -	- -	-0.01	-0.03	-0.02	-0.07	-0.07
Free Cash Flow per Basic Share	- -	-0.01	-0.01	- -	-0.01	- -	- -	- -	- -	- -	-0.01	- -	- -	- -
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	- -	-0.12	-0.11	-0.11	-0.11	-0.11	- -	- -	- -	0.09	0.05	0.03	-0.04	-0.04
Tangible Book Value per Share	- -	0.03	0.02	0.02	0.01	0.01	- -	- -	- -	- -	-0.01	-0.01	-0.02	-0.02
Basic Weighted Avg Shares	- -	27	32	32	35	38	38	38	38	50	59	59	59	59
Sales/Revenue/Turnover	- -	1	1	- -	1	1	- -	- -	- -	- -	- -	- -	- -	- -
Operating Margin (%)	- -	-24.36	-4.53	-45.69	-80.95	-15.08	-13.64	-6.02	-104.32	- -	- -	- -	-7,134.48	-10,378.16
Depreciation Expense	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	1	1	1	- -
Net Income, GAAP	- -	- -	- -	- -	-1	- -	- -	- -	- -	-1	-2	-1	-4	-4
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Profit Margin (%)	- -	-14.59	-32.5	8.49	-83.89	-15.69	-57.66	31.92	-119.87	- -	- -	- -	-35,600.34	-100,366.41
Working Capital	- -	1	1	- -	- -	- -	- -	- -	- -	- -	-1	-1	-1	-1
LT Debt	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Total Equity	- -	1	1	1	1	- -	- -	- -	- -	5	4	3	-1	-1
Return on Invested Capital (%)	- -	- -	- -	-27.67	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Capital (%)	- -	- -	- -	-1.01	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Common Equity (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	-42.75	-42.91	- -	- -

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	- -	- -	-91.01%
Net Income, GAAP	-158.37%	103.54%	309.27%
Free Cash Flow	312.8%	6.49%	-1.01%
Total Cash Common Dividend	- -	- -	- -
Total Equity	-1,203.63%	-2,387.12%	-135.55%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Sina Salehi Pirooz
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: 10022 – 102 Avenue Vancouver BC Canada T8V 0Z7
IPO Date: Feb 18, 2020
Website: genixpharm.com
Similar Companies: Whan In Pharm Co.,Ltd. (016580.KS)
Brooks Laboratories Limited (BROOKS.BO)
Sky Century Investment, Inc. (SKYI)
ShanXi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ)
RedHill Biopharma Ltd. (RDHL)
Karo Pharma AB (publ) (KARO.ST)
Business: Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Renochlor, a dietary supplement to aid in the restoration of kidney health and kidney function; and Sucanon, an insulin sensitizer that lowers blood sugar by increasing the muscle, fat, and liver's sensitivity to insulin. It also markets and sells nutraceuticals and pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels, and spirulina powder, as well as eye ointments and drops. The company was formerly known as Alta Natural Herbs & Supplements Ltd. and changed its name to Genix Pharmaceuticals Corporation in June 2019. Genix Pharmaceuticals Corporation was incorporated in 1993 and is based in Vancouver, Canada.

Company News

newsfilecorp.com
a year ago
Genix Announces TSX-V Approval of Warrant Amendments
newsfilecorp.com
a year ago
Genix Announces Warrant Repricing and Seeks Extension

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	- -	0.02	0.02	0.01	0.02	0.02	0.01	0.01	- -	- -	- -	- -	- -	- -
Basic EPS, GAAP	- -	- -	-0.01	- -	-0.02	- -	-0.01	- -	- -	-0.01	-0.03	-0.02	-0.07	-0.07
Free Cash Flow per Basic Share	- -	-0.01	-0.01	- -	-0.01	- -	- -	- -	- -	- -	-0.01	- -	- -	- -
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	- -	-0.12	-0.11	-0.11	-0.11	-0.11	- -	- -	- -	0.09	0.05	0.03	-0.04	-0.04
Tangible Book Value per Share	- -	0.03	0.02	0.02	0.01	0.01	- -	- -	- -	- -	-0.01	-0.01	-0.02	-0.02
Basic Weighted Avg Shares	- -	27	32	32	35	38	38	38	38	50	59	59	59	59
Sales/Revenue/Turnover	- -	1	1	- -	1	1	- -	- -	- -	- -	- -	- -	- -	- -
Operating Margin (%)	- -	-24.36	-4.53	-45.69	-80.95	-15.08	-13.64	-6.02	-104.32	- -	- -	- -	-7,134.48	-10,378.16
Depreciation Expense	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	1	1	1	- -
Net Income, GAAP	- -	- -	- -	- -	-1	- -	- -	- -	- -	-1	-2	-1	-4	-4
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Profit Margin (%)	- -	-14.59	-32.5	8.49	-83.89	-15.69	-57.66	31.92	-119.87	- -	- -	- -	-35,600.34	-100,366.41
Working Capital	- -	1	1	- -	- -	- -	- -	- -	- -	- -	-1	-1	-1	-1
LT Debt	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Total Equity	- -	1	1	1	1	- -	- -	- -	- -	5	4	3	-1	-1
Return on Invested Capital (%)	- -	- -	- -	-27.67	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Capital (%)	- -	- -	- -	-1.01	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Common Equity (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	-42.75	-42.91	- -	- -

Genix Pharmaceuticals Corporation

Growth Rates

(avg. rate of change)

Company Description

Company News

Growth Rates

(avg. rate of change)

Working Capital

Capital Structure

Quarterly Earnings Per Share

Year

Quarterly Dividends Per Share

Year

Quarterly Revenue

Year

	Jan'24	Apr'24	Jul'24
Total Current Assets	- -	- -	- -
Accounts Receivable, Net	- -	- -	- -
Cash, Cash Equivalents & STI	- -	- -	- -
Inventories	- -	- -	- -
Total Current Liabilities	1	2	2
Payables & Accruals	- -	- -	- -
ST Debt	1	1	1
Deferred Revenue	- -	- -	- -

	Jan'24	Apr'24	Jul'24
ST Debt	1	1	1
LT Borrowings	- -	- -	- -
LT Finance Leases	- -	- -	- -
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	59	59	59
Market Capitalization	1	2	3

Year	Q1	Q2	Q3	Q4	FY
2022	-0.01	- -	- -	- -	-0.02
2023	- -	- -	- -	- -	-0.07
2024	- -	- -	- -	- -	- -